US Stock Insider Trading | TELA Bio disclosed 12 insider transactions on February 24

K-LinePoet · 2026-03-07T05:59:42+00:00

On February 24, 2026, TELA Bio disclosed insider trading activity, with executives and directors selling shares multiple times recently, including Director KOBLISH ANTONY selling 12,500 shares. The company focuses on innovative soft tissue reconstruction solutions, aiming to optimize clinical outcomes and reduce the use of synthetic materials.

K-LinePoet

2026-03-07 05:59:42

Abstract generation in progress

On February 24, 2026, TELA Bio (TELA) disclosed 12 insider transactions. Director KOBLISH ANTONY sold 12,500 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Executive	Firestone Gregory A.	February 21, 2026	Sell	4,189	0.72	3,005.19
February 24, 2026	Executive	Firestone Gregory A.	February 23, 2026	Sell	1,352	0.77	1,035.63
February 24, 2026	Executive	Smeykal Megan	February 19, 2026	Sell	795	0.80	632.03
February 24, 2026	Executive	Smeykal Megan	February 23, 2026	Sell	423	0.77	324.02
February 24, 2026	Director	KOBLISH ANTONY	February 23, 2026	Sell	11,600	0.77	8,909.35
February 24, 2026	Director	KOBLISH ANTONY	February 21, 2026	Sell	12,500	0.72	8,963.20
February 24, 2026	Executive	Smeykal Megan	February 21, 2026	Sell	1,590	0.72	1,140.67
February 24, 2026	Director	KOBLISH ANTONY	February 24, 2026	Sell	3,900	0.79	3,062.28
February 24, 2026	Executive	Talmo Paul	February 23, 2026	Sell	4,061	0.77	3,110.73
February 24, 2026	Executive	Talmo Paul	February 21, 2026	Sell	3,385	0.72	2,428.40

[Company Information]

TELA Bio, Inc. was incorporated on April 17, 2012, in Delaware. The company is a commercial-stage medical technology firm focused on providing innovative soft tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of patients’ own anatomy. Its growing product portfolio aims to leverage the body’s natural healing response while minimizing long-term contact with permanent synthetic materials. The company is committed to delivering advanced technologies with strong economic value propositions to assist surgeons and institutions in providing next-generation soft tissue repair solutions for more patients worldwide.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.